Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adil I Daud

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Nature Medicine|June 27, 2018
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironmentsKevin C Barry, Joy Hsu, Miranda L Broz, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2020
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent MelanomaAlain P Algazi, Christopher G Twitty, Katy K Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Cell|December 28, 2021
Discovering dominant tumor immune archetypes in a pan-cancer censusAlexis J Combes, Bushra Samad, Jessica Tsui, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Nature Medicine|June 27, 2018
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironmentsKevin C Barry, Joy Hsu, Miranda L Broz, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2020
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent MelanomaAlain P Algazi, Christopher G Twitty, Katy K Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Cell|December 28, 2021
Discovering dominant tumor immune archetypes in a pan-cancer censusAlexis J Combes, Bushra Samad, Jessica Tsui, et al.
Pageof 9